Citigroup Initiates Coverage of Cabaletta Bio (CABA) with Buy Recommendation
Nasdaq Fintel reports that on September 5, 2023, Citigroup initiated coverage of Cabaletta Bio (NASDAQ:CABA) with a Buy recommendation.
Analyst Price Forecast Suggests 46.03% Upside
As of August 31, 2023, the average one-year price target for Cabaletta Bio is 20.20. The forecasts range from a low of 14.14 to a high of $35.70. The average price target represents an increase of 46.03% from its latest reported closing price of 13.83.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Cabaletta Bio is 0MM. The projected annual non-GAAP EPS is -1.53.
What is the Fund Sentiment?
There are 172 funds or institutions reporting positions in Cabaletta Bio. This is an increase of 56 owner(s) or 48.28% in the last quarter. Average portfolio weight of all funds dedicated to CABA is 0.27%, a decrease of 9.22%. Total shares owned by institutions increased in the last three months by 47.27% to 41,404K shares. The put/call ratio of CABA is 0.33, indicating a bullish outlook.